RevolKa, a venture-backed biotech company, has just elevated its financial position with a significant boost of Y250m ($1.7m) in Series A extension funding, setting the stage for a rapid acceleration of its drug discovery programmes. This funding round not only supports RevolKa’s financial fortitude but also underscores the potential of its innovative approach to drug […]